日照市-不幸而言中网

赵丽颖微

.appendQr_wra

依托这样的科研实力，以岭药业创新

然而，当前市场给以岭的估值，仍很

往回看，过去5年，以岭药业有5

然而，当前市场给以岭的估值，仍很

当前市值之下，以岭的创新溢价几乎

Well done! You successfully read this important alert message.

Heads up! This alert needs your attention, but it's not super important.

Warning! Best check yo self, you're not looking too good.

Oh snap! Change a few things up and try submitting again.

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration

.appendQr_wrap{border:1pxsolid#E6E6E6;padding:8px;}.appendQr_normal{float:left;}.appendQr_normalimg{width:1

当前市值之下，以岭的创新溢价几乎未被计价，随着业绩显露，价值重估或许只是时间问题往前看：以岭药业创新循环是可持续的，每年研发1-2个新品种，即使放在化药Biotech里也毫不逊色。-仅化药管线中两款临近上市品种（如苯胺洛芬注射液、XY0206片），假设每款贡献10亿收入

估值，该换一套模型了拥有创新药+出海双重bu

也就是说以岭药业可达到300亿市值，且尚未计入